药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Trilostane
Acepromazine
The therapeutic efficacy of Indacaterol can be decreased when used in combination with Acepromazine.
Trilostane
Periciazine
The therapeutic efficacy of Indacaterol can be decreased when used in combination with Periciazine.
Trilostane
Methotrimeprazine
The therapeutic efficacy of Indacaterol can be decreased when used in combination with Methotrimeprazine.
Trilostane
Aripiprazole
The therapeutic efficacy of Indacaterol can be decreased when used in combination with Aripiprazole.
Trilostane
Lumacaftor
The serum concentration of Indacaterol can be decreased when it is combined with Lumacaftor.
Trilostane
Levomilnacipran
Levomilnacipran may increase the tachycardic activities of Indacaterol.
Trilostane
Desvenlafaxine
Desvenlafaxine may increase the tachycardic activities of Indacaterol.
Trilostane
Milnacipran
Milnacipran may increase the tachycardic activities of Indacaterol.
Trilostane
Metergoline
Metergoline may increase the hypertensive and vasoconstricting activities of Indacaterol.
Trilostane
Terguride
Terguride may increase the hypertensive and vasoconstricting activities of Indacaterol.
Trilostane
Dihydroergocryptine
Dihydroergocryptine may increase the hypertensive and vasoconstricting activities of Indacaterol.
Trilostane
Dihydroergocristine
Dihydroergocristine may increase the hypertensive and vasoconstricting activities of Indacaterol.
Trilostane
Dihydroergocornine
Dihydroergocornine may increase the hypertensive and vasoconstricting activities of Indacaterol.
Trilostane
Lysergic acid diethylamide
Lysergic acid diethylamide may increase the hypertensive and vasoconstricting activities of Indacaterol.
Trilostane
Pergolide
Pergolide may increase the hypertensive and vasoconstricting activities of Indacaterol.
Trilostane
Betahistine
The therapeutic efficacy of Indacaterol can be decreased when used in combination with Betahistine.
Trilostane
Atosiban
The risk or severity of adverse effects can be increased when Indacaterol is combined with Atosiban.
Trilostane
Difluocortolone
The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Indacaterol.
Trilostane
Prednisolone acetate
The risk or severity of hypokalemia can be increased when Prednisolone acetate is combined with Indacaterol.
Trilostane
Clobetasol
The risk or severity of hypokalemia can be increased when Clobetasol is combined with Indacaterol.